



Accelerator for first *Proteus*[®]*ONE* Proton Therapy System arrives in Shreveport, Louisiana

First Accelerator Delivered for IBA's New Compact Single-Room PT Solution

Shreveport, Louisiana; Louvain-la-Neuve, Belgium, July 22nd, 2013 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has shipped and delivered the accelerator for the first *Proteus*[®]*ONE* to Willis Knighton Cancer Center.

The *Proteus*[®]*ONE* system has been developed by IBA to allow more patients to access proton therapy. *Proteus*[®]*ONE* is a smaller, less expensive and faster to install proton therapy solution, encompassing the latest technologies, including active scanning. 3 systems have been ordered to date, with the first patient to be treated in 2014.

Olivier Legrain, Chief Executive Officer of IBA commented: "We are delighted to begin onsite installation of this revolutionary proton therapy solution. Making proton therapy smaller and more affordable is a key strategic goal of IBA's and the *Proteus*[®]*ONE* system does exactly that.

Lane R. Rosen, MD, Director of Radiation Oncology at WKCC, added: "We cannot wait to see Intensity Modulated Proton Therapy become an available option for our patients. The timely delivery of this accelerator being delivered demonstrates how IBA and WKCC partner for progress."

Notes to Editors

About Proton Therapy

Proton Therapy is considered the most advanced and targeted cancer treatment due to its superior dose distribution and reduced side effects. Protons deposit the majority of their effective energy within a precisely controlled range within a tumor, sparing healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long-term complications, improving patient outcomes and quality of life.

Today, more than half of proton therapy clinical facilities worldwide utilize IBA systems. This includes 15 proton therapy centers in operation and 11 centers under development. Over 20 000 patients have been treated on IBA equipment – more than all competitor installations combined. www.iba-protontherapy.com



About *Proteus*[®] ONE*

IBA *Proteus*[®] ONE is a compact single-room proton therapy solution. It benefits from the latest technologies of *Proteus*[®] PLUS, developed with top clinical institutions worldwide. *Proteus*[®] ONE is the safest way to compact Intensity Modulated Proton Therapy (IMPT), the most advanced radiotherapy modality. *Proteus*[®] ONE is smaller, more affordable, easier to install, easier to operate and ultimately to finance. With *Proteus*[®] ONE, protons are possible for more patients worldwide. www.iba-proteusone.com

**Proteus*[®] ONE is the brand name of a new configuration of the *Proteus*[®] 235, including some new developments subject to review by Competent Authorities (FDA, European Notified Bodies, et al.) before marketing.

About Willis Knighton Cancer Center

Located in Shreveport Louisiana, the Willis-Knighton Cancer Center is the region's premier cancer treatment facility. WKCC provides a wide range of treatment options for cancer patients including radiation oncology, medical oncology and hematology, surgical oncology and gynecologic oncology. The Cancer Center provides diagnostic services such as PET, X-ray, CT and laboratory. It also offers support groups, counselling, nutritional and educational resources, and community education programs.

About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.

The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room systems. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

For further information, please contact:

IBA

Olivier de Sadeleer

Marketing Manager PT

+32 10 475 890

Investorrelations@iba-group.com

Willis Knighton Cancer Center

Lucy Medvec

Public Relations Manager

+1 318 212 4422

Imedvec@wkhs.com